Search

Displaying results 6151 - 6160 of 10000 in total
  1. Drug

    FavId

    go.drugbank.com/drugs/DB05249
    Investigational

    FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

  2. Drug

    Noxytiolin

    go.drugbank.com/drugs/DB13838
    Approved

    Local antibacterial that probably acts by releasing formaldehyde in aqueous solutions.

  3. Drug

    Praliciguat

    go.drugbank.com/drugs/DB16300
    Investigational

    Praliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).

  4. Drug

    KITE-585

    go.drugbank.com/drugs/DB17409
    Investigational

    KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.

  5. Drug

    AZD8630

    go.drugbank.com/drugs/DB19397
    Investigational

    AZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics

  6. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    It is being investigated to promote or enhance an anti-cancer immune response.

  7. Drug

    Anistreplase

    go.drugbank.com/drugs/DB00029
    ApprovedWithdrawn

    Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase ...

  8. Drug

    Porfiromycin

    go.drugbank.com/drugs/DB06478
    Investigational

    Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.

  9. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in … RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.

  10. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug. … cells, and suppresses tumor growth in glioblastoma xenograft models.